DE60040406D1 - Verfahren zur Herstellung der polymorphen Form II von Sertralin Hydrochlorid - Google Patents

Verfahren zur Herstellung der polymorphen Form II von Sertralin Hydrochlorid

Info

Publication number
DE60040406D1
DE60040406D1 DE60040406T DE60040406T DE60040406D1 DE 60040406 D1 DE60040406 D1 DE 60040406D1 DE 60040406 T DE60040406 T DE 60040406T DE 60040406 T DE60040406 T DE 60040406T DE 60040406 D1 DE60040406 D1 DE 60040406D1
Authority
DE
Germany
Prior art keywords
preparation
polymorphic form
sertraline hydrochloride
sertraline
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60040406T
Other languages
German (de)
English (en)
Inventor
Der Schaaf Paul Adriaan Van
Franz Schwarzenbach
Hans-Joerg Kirner
Martin Szelagiewicz
Claudia Marcolli
Andreas Burkhard
Regine Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60040406(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Holding AG filed Critical Ciba Holding AG
Application granted granted Critical
Publication of DE60040406D1 publication Critical patent/DE60040406D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60040406T 1999-10-29 2000-10-23 Verfahren zur Herstellung der polymorphen Form II von Sertralin Hydrochlorid Expired - Fee Related DE60040406D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810981 1999-10-29
PCT/EP2000/010416 WO2001032601A1 (en) 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride

Publications (1)

Publication Number Publication Date
DE60040406D1 true DE60040406D1 (de) 2008-11-13

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040406T Expired - Fee Related DE60040406D1 (de) 1999-10-29 2000-10-23 Verfahren zur Herstellung der polymorphen Form II von Sertralin Hydrochlorid

Country Status (17)

Country Link
US (2) US6872853B1 (enExample)
EP (1) EP1224160B1 (enExample)
JP (1) JP2003513062A (enExample)
CN (1) CN1384816A (enExample)
AR (1) AR026293A1 (enExample)
AT (1) ATE409684T1 (enExample)
AU (1) AU1386301A (enExample)
CA (1) CA2387135A1 (enExample)
DE (1) DE60040406D1 (enExample)
HU (1) HUP0203559A3 (enExample)
IL (2) IL149050A0 (enExample)
MX (1) MXPA02004255A (enExample)
MY (1) MY141509A (enExample)
TR (1) TR200201146T2 (enExample)
TW (1) TWI260315B (enExample)
WO (1) WO2001032601A1 (enExample)
ZA (1) ZA200203254B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632472A1 (en) * 1998-11-27 2006-03-08 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
DE69929462T2 (de) * 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
WO2001045692A1 (en) * 1999-12-21 2001-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
EP1772144A3 (en) * 1999-12-21 2007-08-15 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IN192343B (enExample) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
CA2448279A1 (en) 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
WO2003093217A1 (en) * 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
MXPA04011375A (es) * 2002-06-27 2005-02-14 Interdigital Tech Corp Controlador de red de radio para intercambio de informacion de equipo.
WO2005000786A1 (en) 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US7893300B2 (en) 2003-11-04 2011-02-22 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
WO2007008317A2 (en) * 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
CN103458871B (zh) 2011-04-07 2015-05-13 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的调理剂组合物
WO2012138710A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
WO2012138696A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
CA3194468A1 (en) 2020-10-16 2022-04-21 Johan Smets Consumer product compositions comprising a population of encapsulates
MX2023004232A (es) 2020-10-16 2023-04-21 Procter & Gamble Composiciones de productos de consumo con al menos dos poblaciones de encapsulados.
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
CA2323629A1 (en) 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
DE69929462T2 (de) 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
WO2001045692A1 (en) 1999-12-21 2001-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Also Published As

Publication number Publication date
ATE409684T1 (de) 2008-10-15
MY141509A (en) 2010-05-14
ZA200203254B (en) 2003-07-22
TWI260315B (en) 2006-08-21
AU1386301A (en) 2001-05-14
IL149050A0 (en) 2002-11-10
MXPA02004255A (es) 2002-10-17
EP1224160A1 (en) 2002-07-24
US20040132828A1 (en) 2004-07-08
CN1384816A (zh) 2002-12-11
HUP0203559A2 (hu) 2003-03-28
AR026293A1 (es) 2003-02-05
US6939992B2 (en) 2005-09-06
WO2001032601A1 (en) 2001-05-10
US6872853B1 (en) 2005-03-29
JP2003513062A (ja) 2003-04-08
EP1224160B1 (en) 2008-10-01
IL149050A (en) 2007-03-08
HUP0203559A3 (en) 2008-01-28
TR200201146T2 (tr) 2004-12-21
CA2387135A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
DE60040406D1 (de) Verfahren zur Herstellung der polymorphen Form II von Sertralin Hydrochlorid
DE59905881D1 (de) Verfahren zur herstellung von aminen
DE50000852D1 (de) Verfahren zur Herstellung von Aminen
DE19983486T1 (de) Verfahren zur Herstellung von Citalopram
DE69906389D1 (de) Verfahren zur herstellung von citalopram
DE60124482D1 (de) Verfahren zur Herstellung von Xylylendiamin
DE50003632D1 (de) Verfahren zur herstellung von l-phenylephrinhydrochlorid
DE69803646D1 (de) Verfahren zur Herstellung der epsilon polymorphischen Form des Hexanitrohexaazaisowurtzitan
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
DE60104244D1 (de) Verfahren zur Herstellung von Amiden
DE60040720D1 (de) Verfahren zur Herstellung von Nitrilverbindungen
DE60116874D1 (de) Verfahren zur herstellung von (r)-2-alkyl-3-phenyl-1-propanolen
DE60024372D1 (de) Verfahren zur Herstellung von Tetraorganooxysilanen
DE60033877D1 (de) Verfahren zur Herstellung von Dimethylsulfoxid
DE50005403D1 (de) Verfahren zur Herstellung von Monoisopropylamin
DE60002784D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin
DE60022565D1 (de) Verfahren zur Herstellung von Polyaminzusammensetzungen
DE50108607D1 (de) Verfahren zur Herstellung von 4-Aminodiphenylamin
DE60102763D1 (de) Verfahren zur Herstellung von Dihydroperimidin-Squarainverbindungen
DE60043610D1 (de) Verfahren zur herstellung von l-lysin
DE60011021D1 (de) Verfahren zur Herstellung von aromatischen Diaminen/aromatischen Dicarboxylaten
DE60031231D1 (de) Verfahren zur Herstellung von 2-Alkyl-4-Isothiazolin-3-onen
DE60029847D1 (de) Verfahren zur Herstellung von erythro 3-Amino-2-hydroxybuttersäurederivaten
DE60004119D1 (de) Verfahren zur Herstellung von Pentaacetyl-beta-D-Glucopyranose

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee